Visgenx
生物技术研究
Santa Cruz，California 187 位关注者
Therapeutics for Dry Age-Related Macular Degeneration
关于我们
Visgenx is developing therapeutics based on increasing expression of a gene known as ELOVL2 which has been shown to regulate aging in the retina and other tissues. Our lead indication is Dry Age-Related Macular Degeneration (Dry AMD).
- 网站
-
www.visgenx.com
Visgenx的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Santa Cruz，California
- 类型
- 私人持股
- 创立
- 2018
- 领域
- Gene Therapy
地点
-
主要
获取路线
250 Natural Bridges Dr
US，California，Santa Cruz，95060
Visgenx员工
动态
-
Visgenx to Present at the 9th Annual Retinal Cell and Gene Therapy Innovation Summit https://lnkd.in/gQP5Ua3m